Market Overview

4 More Biotech Secondaries Traders Are Watching

Related ALNY
Why Investors Should Take Another Look At Alnylam Pharmaceuticals
Data Monitoring Committee Determines Alnylam's ENDEAVOUR Trial May Continue
Related ARNA
Watch These 5 Huge Call Purchases In Thursday Trade
Earnings Scheduled For August 8, 2016

There are a number of biotechs this week looking to raise money. Below are details on four.

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) priced its secondary offering at $95 per share. The underwriters were J.P. Morgan and Deutsche Bank. The company raised $450 million and is planning to use the money to expand its pipeline.

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) offered 21 million shares and priced at $5 per share. The underwriters were Jeffries and Piper Jaffray.

The capital raise comes after the stock rallied on January 7 when the company announced that its autoimmune disease drug APD334 showed positive results in a Phase 1b trial.

After the close on Tuesday, Intrexon Corp (NYSE: XON) announced it will be offering $150 million in stock. The underwriters are J.P. Morgan, Bank of America Merrill Lynch, Jeffries, Griffin Securities, and Mizuho Securities.

The raise comes after the company announced it would be partnering with ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) and MD Anderson to develop CAR-T therapies. As a part of the agreement, Intrexon owes MD Anderson $50 million.

The offering will price on Wednesday night and trade Thursday.

Keryx Biopharmaceuticals (NASDAQ: KERX) is offering $100 million in stock and the sole underwriter is J.P. Morgan. On December 22, the company announced the commercial launch of Auryxia tablets in the United States.

The offering will price Wednesday night and trade Thursday.

Posted-In: Long Ideas Previews FDA Trading Ideas


Related Articles (ALNY + ARNA)

View Comments and Join the Discussion!